[Epirubicin-based combination chemotherapy in the treatment of non-Hodgkin's lymphoma: with emphasis of elderly patients].
Twenty-four patients with non-Hodgkin's lymphoma aged 60 years and older were treated with epirubicin-based combination chemotherapy. Complete remission was obtained in nineteen (83%) of 23 patients with measurable disease. Of these complete responders seventeen patients with localized disease attained complete remission. No patients received radiation therapy after chemotherapy. The survival rate was 78% at 50 months in patients with the localized disease. The median follow-up time is 40 months, ranging from 13 to 65 months. All of the localized disease were treated in the out-patient clinic and no patients died of chemotherapy-related infectious complications. No severe infection such as either bacteremia or pneumonia occurred. It was concluded that epirubicin-based combination chemotherapy was highly effective in patients with localized non-Hodgkin's lymphoma.
Sampi
K
K
Otolaryngology Clinic, Saitama Cancer Center.
Takouda
K
K
Hattori
M
M
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage
D015251:Epirubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014751:Vindesine